Maryka Quik

Summary

Affiliation: The Parkinson's Institute
Country: USA

Publications

  1. ncbi Nicotinic receptors and Parkinson's disease
    M Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Eur J Pharmacol 393:223-30. 2000
  2. ncbi Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey
    M Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neuroscience 113:213-20. 2002
  3. ncbi Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Ann Neurol 62:588-96. 2007
  4. ncbi Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, California 94089 1605, USA
    Mol Pharmacol 63:1169-79. 2003
  5. ncbi Nicotine and nicotinic receptors; relevance to Parkinson's disease
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Neurotoxicology 23:581-94. 2002
  6. ncbi Nicotinic receptors as CNS targets for Parkinson's disease
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Biochem Pharmacol 74:1224-34. 2007
  7. ncbi Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA
    Maryka Quik
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089 1605, USA
    Mol Pharmacol 67:32-41. 2005
  8. ncbi Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage
    M Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Neuroscience 112:619-30. 2002
  9. ncbi Nicotine neuroprotection against nigrostriatal damage: importance of the animal model
    Maryka Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Trends Pharmacol Sci 28:229-35. 2007
  10. ncbi Nicotine and Parkinson's disease: implications for therapy
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, California, USA
    Mov Disord 23:1641-52. 2008

Detail Information

Publications54

  1. ncbi Nicotinic receptors and Parkinson's disease
    M Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Eur J Pharmacol 393:223-30. 2000
    ..The results show that nicotine pretreatment protected against dopaminergic nigral neural degeneration. These data suggest that nicotinic receptor ligands may be useful in Parkinson's disease therapy...
  2. ncbi Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey
    M Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neuroscience 113:213-20. 2002
    ..These results thus question the importance of preproenkephalin mRNA in the pathogenesis of this disabling complication of L-DOPA therapy in Parkinson's disease...
  3. ncbi Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Ann Neurol 62:588-96. 2007
    ..Our objective, therefore, was to determine whether nicotine treatment reduced levodopa-induced dyskinesias...
  4. ncbi Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, California 94089 1605, USA
    Mol Pharmacol 63:1169-79. 2003
    ..These data suggest that the declines in nAChR sites observed in Parkinson's disease brains may be of functional significance...
  5. ncbi Nicotine and nicotinic receptors; relevance to Parkinson's disease
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Neurotoxicology 23:581-94. 2002
    ..These data suggest that nicotinic receptor ligands directed to alpha6* nicotinic receptors might be particularly relevant for Parkinson's disease therapeutics...
  6. ncbi Nicotinic receptors as CNS targets for Parkinson's disease
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Biochem Pharmacol 74:1224-34. 2007
    ..These observations suggest that development of nAChR agonists or antagonists targeted to alpha6beta2-containing nAChRs may represent a particularly relevant target for Parkinson's disease therapeutics...
  7. ncbi Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA
    Maryka Quik
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089 1605, USA
    Mol Pharmacol 67:32-41. 2005
    ..Overall, these results suggest that drugs targeting non-alpha7 nicotinic receptors may be useful in the treatment of disorders characterized by nigrostriatal dopaminergic damage, such as Parkinson's disease...
  8. ncbi Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage
    M Quik
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Neuroscience 112:619-30. 2002
    ..However, nicotinic receptor ligands with a broader specificity may be more important if receptors in the substantia nigra play a dominant role in controlling nigrostriatal activity...
  9. ncbi Nicotine neuroprotection against nigrostriatal damage: importance of the animal model
    Maryka Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Trends Pharmacol Sci 28:229-35. 2007
    ..These findings highlight the need to use the appropriate animal model and treatment conditions when testing putative neuroprotective agents...
  10. ncbi Nicotine and Parkinson's disease: implications for therapy
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, California, USA
    Mov Disord 23:1641-52. 2008
    ....
  11. ncbi Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94089 1605, USA
    J Pharmacol Exp Ther 316:481-9. 2006
    ....
  12. ncbi Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey
    M Quik
    The Parkinson s Institute, Sunnyvale, California 94089, USA
    J Neurosci 21:5494-500. 2001
    ..These data suggest that the development of ligands directed to nAChR subtypes containing alpha3 and/or alpha6 subunits may yield a novel treatment strategy for parkinsonian patients with nigrostriatal dopaminergic degeneration...
  13. ncbi Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, California, USA
    J Neurochem 98:1866-75. 2006
    ..These data further support the possibility that nicotine contributes to the lower incidence of Parkinson's disease in smokers...
  14. ncbi Multiple roles for nicotine in Parkinson's disease
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94085, United States
    Biochem Pharmacol 78:677-85. 2009
    ..Treatment with nAChR ligands directed to these subtypes may thus yield optimal therapeutic benefit for Parkinson's disease, with a minimum of adverse side effects...
  15. ncbi Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization
    M Quik
    The Parkinson s Institute, Sunnyvale, California 94089, USA
    J Comp Neurol 425:58-69. 2000
    ..These findings have implications for the development of drug therapies for neurological disorders, such as Alzheimer's and Parkinson's disease, in which nicotinic receptors are decreased...
  16. ncbi Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, CA 94085, USA
    J Mol Neurosci 40:105-13. 2010
    ..These observations may have therapeutic implications for Parkinson's disease...
  17. ncbi Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs
    Mirium Khwaja
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    J Neurochem 100:180-90. 2007
    ..Moreover, these data support epidemiological findings that environmental influences can elicit opposing effects on nigrostriatal dopaminergic integrity...
  18. ncbi Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys
    Luping Z Huang
    Basic Research Department, The Parkinson s Institute, Sunnyvale, California 94085, USA
    J Neurochem 109:826-37. 2009
    ..The observations suggest that protection against nigrostriatal damage may be linked to striatal alpha6alpha4beta2* nAChRs...
  19. ncbi Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage
    Sarah E McCallum
    The Parkinson's Institute, 1170 Morse Ave, Sunnyvale, CA 94089-1605, USA
    Mol Pharmacol 68:737-46. 2005
    ..Maintenance of function in putamen, a region with a selective loss of dopaminergic terminals, may be important in PD...
  20. ncbi Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine
    Tanuja Bordia
    The Parkinson's Institute, 1170 Morse Ave, Sunnyvale, CA 94089-1605, USA
    J Pharmacol Exp Ther 319:285-92. 2006
    ..Such findings suggest that nicotine or nicotinic agonists may be of therapeutic value in Parkinson's disease...
  21. ncbi Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment
    Sarah E McCallum
    The Parkinson's Institute, Sunnyvale, California 94089, USA
    J Neurochem 96:1028-41. 2006
    ..Such knowledge is important for understanding nicotine dependence and the consequences of nicotine administration for the treatment of neurological disorders...
  22. ncbi Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage
    Jennifer M Kulak
    The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089-1605, USA
    J Pharmacol Exp Ther 303:633-9. 2002
    ....
  23. ncbi Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum
    Kathryn O'Leary
    The Parkinson s Institute, 675 Almanor Ave, Sunnyvale, CA 94085 2934, USA
    J Pharmacol Exp Ther 325:646-54. 2008
    ..These data demonstrate that cotinine functionally discriminates between two alpha3/alpha6beta2* nAChRs in monkey striatum, with the cotinine-insensitive alpha3/alpha6beta2* nAChR preferentially vulnerable to nigrostriatal damage...
  24. ncbi Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites
    Jennifer M Kulak
    The Parkinson's Institute, Sunnyvale, California 94089-1605, USA
    Mol Pharmacol 61:230-8. 2002
    ....
  25. ncbi Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum
    Tanuja Bordia
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089 1605, USA
    Mol Pharmacol 72:52-61. 2007
    ..This latter nAChR subtype, identified with alpha-CtxMII E11A, may therefore provide a unique marker for dopaminergic terminals particularly sensitive to nigrostriatal degeneration in Parkinson's disease...
  26. ncbi L-DOPA treatment modulates nicotinic receptors in monkey striatum
    Maryka Quik
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089 1605, USA
    Mol Pharmacol 64:619-28. 2003
    ..These declines in nAChRs with l-DOPA may be relevant to both the therapeutic and side effect profiles of l-DOPA therapy in Parkinson's disease...
  27. ncbi 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes
    Jennifer M Kulak
    The Parkinson's Institute, Sunnyvale, California 94089-1605, USA
    J Neurochem 81:403-6. 2002
    ..These data are important for identifying alterations in nicotinic receptor subtypes in Parkinson's disease and other basal ganglia disorders both in in vitro and in in vivo imaging studies...
  28. ncbi Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys
    A Lai
    The Parkinson's Institute, Sunnyvale, CA 94089, USA
    Neuroscience 127:399-408. 2004
    ..The present data show that recovery of 125I-alpha-CtxMII receptors occurs in parallel with the dopamine transporter, indicating that these nicotinic receptors sites are localized to presynaptic dopamine terminals in both species...
  29. ncbi Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells
    Karen Riveles
    The Parkinson s Institute, Sunnyvale, CA 94085, USA
    Neurotoxicology 29:421-7. 2008
    ..These data suggest that nicotine may be of potential therapeutic value for Parkinson's disease...
  30. ncbi The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates
    Heather Cox
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Exp Neurol 205:101-7. 2007
    ..These data suggest that kappa-opioid agonists such as U50,488 may not be clinically useful antidyskinetic agents because they also reverse the anti-parkinsonian effect of l-dopa...
  31. ncbi Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration
    M Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neuroscience 100:63-72. 2000
    ....
  32. ncbi Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice
    Albert Lai
    The Parkinson's Institute, Sunnyvale, California 94089-1605, USA
    Mol Pharmacol 67:1639-47. 2005
    ..The present data suggest that the alpha6* nAChR subtype represents a key factor in the control of dopamine release from striatum, which adapts to long-term nicotine treatment by down-regulation of alpha6* receptor sites and function...
  33. ncbi Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys
    Sarah E McCallum
    The Parkinson's Institute, 1170 Morse Ave, Sunnyvale, CA 94089-1605, and Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Pharmacol Exp Ther 318:381-8. 2006
    ....
  34. ncbi Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates
    Maryka Quik
    The Parkinson s Institute, Sunnyvale, California 94089, USA
    J Neurosci 26:4681-9. 2006
    ..These cellular alterations may underlie the ability of nicotine to maintain/restore normal function with nigrostriatal damage...
  35. ncbi Nicotine as a potential neuroprotective agent for Parkinson's disease
    Maryka Quik
    Center for Health Sciences, SRI International, Menlo Park, California, USA
    Mov Disord 27:947-57. 2012
    ..Altogether, these findings suggest that nicotine and nAChR drugs represent promising therapeutic agents for the management of Parkinson's disease...
  36. ncbi Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum
    Kathryn T O'Leary
    The Parkinson s Institute, 675 Almanor Ave, Sunnyvale, CA 94085 2934, USA
    J Pharmacol Exp Ther 327:124-9. 2008
    ..The finding that paraquat treatment has a negative impact on striatal nAChR-mediated dopaminergic activity in monkeys but not mice indicates the need for determining the effects of pesticides in higher species...
  37. ncbi Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function
    Xiomara A Perez
    The Parkinson s Institute, 675 Almanor Avenue, Sunnyvale, CA 94085, USA
    Mol Pharmacol 74:844-53. 2008
    ..Thus, alpha6beta2(*) nAChR subtypes may represent important targets for smoking cessation therapies and neurological disorders involving these receptors such as Parkinson's disease...
  38. ncbi Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment
    Xiomara A Perez
    The Parkinson s Institute, Sunnyvale, CA 94085, USA
    Mol Pharmacol 75:938-46. 2009
    ..These findings have implications for the development of treatments for addiction and neurological disorders with nAChR dysfunction...
  39. ncbi Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates
    Xiomara A Perez
    The Parkinson s Institute, Sunnyvale, California 94085, USA
    J Neurochem 105:1861-72. 2008
    ..Such an interpretation is supported by the results of dopamine turnover studies. This enhanced pre-synaptic dopaminergic activity may be important in maintaining normal motor function during the initial stages of Parkinson's disease...
  40. ncbi Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease
    Tanuja Bordia
    The Parkinson s Institute, 675 Almanor Ave, Sunnyvale, CA 94085 2934, USA
    J Pharmacol Exp Ther 327:239-47. 2008
    ..These results suggest that either intermittent or constant nicotine treatment may be useful in the treatment of L-DOPA-induced dyskinesias in patients with Parkinson's disease...
  41. ncbi Smoking, nicotine and Parkinson's disease
    Maryka Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Trends Neurosci 27:561-8. 2004
    ..An understanding of the molecular basis for the reduced occurrence of PD in tobacco users is crucial for the development of intervention strategies to reduce or halt disease progression...
  42. ncbi Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment
    M Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089
    Neuroscience 98:263-73. 2000
    ....
  43. ncbi The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates
    Daniel M Togasaki
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    J Neurosci Methods 145:159-66. 2005
    ..These results indicate that the Webcam system is reliable under both untreated and experimental conditions and is an excellent method for quantifying motor activity in animals...
  44. ncbi Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment
    L He
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089, USA
    Neuroscience 99:697-704. 2000
    ....
  45. ncbi Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys
    L Chen
    The Parkinson's Institute, Basic Research Department, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neuroscience 132:409-20. 2005
    ..The positive correlation with LIDs suggests this may represent an intracellular signaling mechanism underlying these movement abnormalities...
  46. ncbi Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa
    Daniel M Togasaki
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neuropharmacology 48:398-405. 2005
    ..Thus, this study suggests that diminished buffering capacity for dopamine could play a role in the development of dyskinesias, and that an endogenous mechanism might exist that ameliorates dyskinesias...
  47. ncbi Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys
    Albert Hsu
    The Parkinson's Institute, 1170 Morse Ave, Sunnyvale, CA 94089, USA
    J Pharmacol Exp Ther 311:770-7. 2004
    ..These results suggest that BP897 may be less effective than originally anticipated for treating LIDs in Parkinson's disease...
  48. ncbi Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture
    G Jeyarasasingam
    The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neuroscience 109:275-85. 2002
    ....
  49. ncbi Levodopa induces dyskinesias in normal squirrel monkeys
    D M Togasaki
    The Parkinson s Institute, Sunnyvale, CA 94089, USA
    Ann Neurol 50:254-7. 2001
    ..The present data demonstrate that preexisting nigrostriatal damage is not necessary for the development of levodopa-induced dyskinesias...
  50. ncbi Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum
    M Quik
    The Parkinson s Institute, Sunnyvale, California 94089, USA
    J Neurochem 88:668-79. 2004
    ..In summary, these results show that alpha-conotoxinMII-sensitive sites are present in human striatum and that there are high- and low-affinity subtypes which are both decreased in Parkinson's disease...
  51. ncbi Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates
    S E McCallum
    The Parkinson's Institute, Sunnyvale, California 94089, USA
    J Neurochem 96:960-72. 2006
    ..These combined compensatory mechanisms help explain the finding that Parkinson's disease symptomatology develops only with major losses of striatal dopamine...
  52. ncbi Targeting nicotinic receptors for Parkinson's disease therapy
    Maryka Quik
    Center for Health Sciences, SRI International, California 94025, USA
    CNS Neurol Disord Drug Targets 10:651-8. 2011
    ..These combined findings suggest that nicotine and nAChR drugs offer the possibility of improved therapeutics for Parkinson's disease...
  53. ncbi Nicotine administration reduces striatal MPP+ levels in mice
    M Quik
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089, USA
    Brain Res 917:219-24. 2001
    ..In summary, these results suggest that nicotine may exert its neuroprotective action against nigrostriatal degeneration, at least in part, by decreasing striatal MPP+ levels...
  54. ncbi Guidelines on nicotine dose selection for in vivo research
    Shannon G Matta
    Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, 874 Union Avenue, Crowe 115, Memphis, TN 38163, USA
    Psychopharmacology (Berl) 190:269-319. 2007
    ..In many cases, such discrepancies could be attributed to the complex variables comprising species-specific in vivo responses to acute or chronic nicotine exposure...